Pharmacogenetic considerations in antiplatelet therapy
نویسندگان
چکیده
منابع مشابه
Pharmacogenetic considerations in diseases of cardiac ion channels.
Phenotypic variation within a species arises from differences in genetic makeup between individuals. This inherent diversity empowers the species as a whole to explore and expand into new environmental niches and also to survive new stressors within an ever-changing environment. Paradoxically, one class of stressors currently challenging the human population is therapeutic drugs: medications de...
متن کاملClinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Despite the proven benefits of using antiplatelet therapy in patients undergoing percutaneous coronary intervention (PCI), a number of key questions remain to be answered. In recent years, clopidogrel dosing strategies among such patients have evolved considerably, with newer approaches involving loading doses prior to PCI and increases in the time interval and loading dosage in an effort to ov...
متن کاملAntiplatelet therapy in cardiovascular disease.
Platelet activation and aggregation are considered to be central to arterial thrombus formation. Antiplatelet therapy is therefore important for both the treatment and prevention of cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-oxygenase and the conversion of arachidonic acid to the potent platelet agonist thromboxane A(2) but does not prevent...
متن کاملAntiplatelet Therapy – Recent Advances
Haemostatic function of platelets is vital & their pathological role is potentially lethal. In pathological states there is over activation and aggregation of blood platelets resulting in atherothrombosis causes various states from angina to acute coronary syndromes, stroke and peripheral artery diseases. Platelets are anuclear subcellular fragments derived from megakaryocytes that circulate in...
متن کاملPerioperative antiplatelet therapy.
Aspirin is recommended as a lifelong therapy that should never be interrupted for patients with cardiovascular dis- ease. Clopidogrel therapy is mandatory for six weeks after placement of bare-metal stents, three to six months after myocardial infarction, and at least 12 months after placement of drug-eluting stents. Because of the hypercoagulable state induced by surgery, early withdrawal of a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Precision Medicine and Drug Development
سال: 2020
ISSN: 2380-8993
DOI: 10.1080/23808993.2020.1768844